tbuckley/cabot-search huggingface dataset:
BIOMECHANICAL DIFFERENCES BETWEEN CASES WITH CECS AND ASYMPTOMATIC CONTROLS DURING RUNNING
Authors: A Roberts, D Roscoe, D Hulse, A Bennett, S Dixon
Journal: British Journal of Sports Medicine (2016)

Chronic exertional compartment syndrome (CECS) presents as exertional pain in the lower limb as a result of elevation of intramuscular compartment pressure. Treatment of CECS through a change in running style has recently been suggested to improve symptoms however no primary research has investigated whether patients with CECS run differently to controls. This study aimed to compare the kinematic differences in cases with CECS and controls. 20 men with symptoms of CECS of the anterior compartment and 20 asymptomatic male controls participated. Barefoot and shod running 3D kinematics; and anthropometry were compared. Cases were heavier than controls with no differences in height. This result contrasts with our recent study that reported that cases in that cohort were on average 10 cm shorter than controls; with no differences in weight. As such we have previously suggested that small stature may be a risk factor for CECS in the military. Further work is now needed to provide more robust data on this theory. Our findings are the first to demonstrate that CECS patients run with a different gait pattern to controls. Cases displayed less anterior trunk lean and less anterior pelvic tilt throughout the whole gait cycle and a more upright shank inclination angle during late swing. Cases demonstrated greater step length and stance time, although this was not consistent across conditions. Alterations to running style that have been used in an attempt to reduce the anterior compartment activity of CECS patients typically encouraged greater forward lean; along with other more distal changes. Clinical observations have also suggested increased ankle dorsiflexion and reduced heel lift during swing phase. The differences reported in this study only partially match the anecdotal observations previously described in the literature. However, no consistent differences were found at the ankle joint. Our results therefore demonstrate the importance of acquiring higher level evidence before implementing gait re-education programs. Assuming the reported interventions reduce anterior compartment muscle activity, they may simply modify activity, rather than changing pathological gait. The longer stride length is a continuing theme in this population and as such we believe this may be a key component in the development of the condition.
FOAM ROLLING INCREASES SKELETAL MUSCULAR EFFICIENCY WITHOUT AFFECTING RANGE OF MOTION
Authors: LJ Macgregor, AM Hunter
Journal: British Journal of Sports Medicine (2016)

Foam rolling (FR) has been shown to alleviate some symptoms of exercise-induced muscle damage, and has been suggested to increase range of movement (ROM) without negatively impacting strength. However, the exact mechanisms of action are unclear. The aim of this study was to investigate mechanisms associated with a single acute bout of FR, as well as repeated bouts of FR, on healthy rested muscle. Muscle stiffness of vastus lateralis and rectus femoris of 16 healthy active male volunteers were measured using tensiomyography (TMG). Knee extension maximal voluntary contraction (MVC) and knee flexion ROM were also assessed, and surface electromyography (sEMG) was recorded during a submaximal isometric contraction (50% of MVC). Measures were performed before and after (0, 15 and 30 minutes) either a 2 minute rest period (control) or a 2 minute bout of FR, performed on quadriceps; each condition was repeated for 3 consecutive days, with 7 days between conditions. MVC was reduced in control compared to with FR (p&lt;0.001), ROM was not altered (p=0.125). Dm of the VL (p=0.001) was elevated on the third day of FR. sEMG was reduced (p&lt;0.01) 0, 15 and 30 minutes after FR compared to control. Following FR, MVC was elevated compared to control and sEMG was transiently reduced during a submaximal task. This suggests that the activation efficiency of the involved muscles has been increased by FR, which has spared the decline in MVC, observed in control, due to fatigue from repeated efforts.
Metastatic germ cell tumours (mGCT) treatment and outcomes in patients aged ≥ 50 years in west of Scotland.
Authors: Ishtiaq Husain Zubairi, Asa Dahle-Smith, Andrew Davis, Nicola Thomson, Ashita Waterston, Jeff White
Journal: Journal of Clinical Oncology (2016)

e21567 Background: GCTs are rare cancers mainly affecting young males. There is evidence for increasing incidence in older men for whom optimal treatment and outcomes are not extensively studied. We report characteristics and outcomes of 42 patients (pts) aged ≥ 50 years, who have received first line chemotherapy for mGCTs at The Beatson West of Scotland Cancer Centre, Glasgow. Methods: 42 pts 50 years (yrs) of age or older who received chemotherapy from 1st January 2007 to 31st December 2014 for mGCT were included. Data from pharmacy electronic records were collected using a proforma. Results: Median age at diagnosis was 56 yrs (51-61 yrs). 29 (69%) were good, 7 (17%) intermediate and 6 (14%) poor prognosis. 20 pts (48%) had no co morbidities. In remainder main co morbidities were diabetes mellitus 12% , ischaemic heart disease 10%, hypertension 10%, chronic obstructive airways disease 5% and cognitive impairment 5%. Ten (24%) pts were smokers. Main chemotherapies given were EP x4 (41%), BE500P x 3 (26%), Carboplatin and Etoposide (12%). 36 pts (86 %) commenced at 100% dose. 9 (21%) had dose reductions in subsequent cycles and 9 (21%) had dose delays. Most pts (n=30, 74%) were able to continue treatment without any delays. Information about dose delays was not available for 2 (5 %) of the pts. Relative dose intensities (RDI) were 0.93 (SD 0.093) for EP x4, 0.91 (SD 0.22) for BE500P x 3 and 0.65 ( SD 0.4) for Carboplatin Etoposide. Overall mean relative dose intensity was 0.88. 32 pts (74%) received GCSF support from first cycle. 5 pts never received GCSF. There were 20 (48%) complete responses, 18 (43%) partial responses, 1 stable disease, 1 progression and 1 death on chemotherapy. 5 pts (12%) had surgery post chemo. Overall survival was 91% (median follow up of 55 months – data censored 31 Dec 2015) Conclusions: Pts aged ≥ 50 yrs with metastatic GCT should be considered for combination platinum based chemotherapy with appropriate dose modifications and supportive care. Majority received chemotherapy with no significant complications. Survival rate with median follow up of 4.5 years was 91%. Histologic distribution. Histology n % Seminoma 18 43 NSGCT 7 17 Mixed seminoma/NSGCT 14 33 Transformed teratoma 1 2 Mediastinal primary 1 2 Other 1 2
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Authors: Grant D. Stewart, Michael Aitchison, Axel Bex, James Larkin, Claire Lawless, Arnaud Méjean, Paul Nathan, Grenville Oades, Jean-Jacques Patard, James Paul, Alain Ravaud, Bernard Escudier
Journal: European Urology (2016)
P0720 : Improvement of advanced liver fibrosis and regression of liver cirrhosis in patients with hepatitis C genotype 1 after HCV protease inhibitor-based triple therapy
Authors: F. Sáez-Royuela, P. Linares, L.A. Cervera, C. Almohalla, F. Jorquera, I. García, A. Moncada, G. Karpman, E. Badia, M.A.A. Vallecillo, S. Lorenzo, J.L. Olcoz
Journal: Journal of Hepatology (2015)
Adverse Immunologic, Cytogenetic, and Molecular Features of AML in Elderly Patients Could Be Overcome by Allogeneic Hematopoietic Cell Transplantation Following Reduced Intensity Conditioning
Authors: Haifa Kathrin Al-Ali, Nadja Jaekel, Rainer Krahl, Claudia Nehring, Cornelia Becker, Leanthe Braunert, Sabine Leiblein, Jeanett Edelmann, Georg Franke, Wolfram Poenisch, Thoralf Lange, Dietger Niederwieser
Journal: Blood (2011)
CHIR258: A Multitargeted Growth Factor Receptor Tyrosine Kinase (RTK) Inhibitor Induces Significant Apoptosis of Human FLT3 ITD Acute Myelogenous Leukemia Cells In Vitro and in Vivo.
Authors: Daniel L. Menezes, Marion Wiesmann, Sang Hoon Lee, Isabelle Lee, Jing Peng, Yan Tang, Helen Ye, Yoko Oei, Cheryl Goldbeck, Evelyn N. Garrett, Carla Heise
Journal: Blood (2004)
Predictive Value of FcR Polymorphisms
Authors: Riccardo Dolcetti
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Hematopoietic Recovery after Allogeneic Transplantation Using G-CSF-Mobilized and Cryopreserved Peripheral Blood Stem Cells (PBSC).
Authors: Daigo Akahane, Yasushi Onishi, Sung Won, Masahiro Kami, Shin-ichiro Mori, Yuji Heike, Yoichi Takaue, Ryuji Tanosaki
Journal: Blood (2004)
Unusual Presentations of Malignancy
Authors: Edgar G. Miranda, Shohreh Iravani, Donald C. Doll
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.13.3290 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11432898 Unusual Presentations of Malignancy Case 2. Breast Plasmacytoma in a Patient with Human Immunodeficiency Virus Edgar G. MirandaxEdgar G. MirandaSearch for articles by this author , Shohreh IravanixShohreh IravaniSearch for articles by this author , Donald C. DollxDonald C. DollSearch for articles by this author Show More James A. Haley Veterans Affairs Hospital, Tampa, FL https://doi.org/10.1200/JCO.2001.19.13.3290 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin
Authors: Soraya Carrancio, Jennifer A Markovics, Piu Wong, Jim Leisten, Matthew C Groza, Heather K Raymon, Carla Heise, Rajesh Chopra, Tom O Daniel, Victoria Sung
Journal: Blood (2012)
The T Cell Receptor As An Oncogene: Thymic Expression Of Self-Reactive T Cell Receptors Targeting Survivin Induces T-Cell Lymphoblastic Leukmia
Authors: Yongzhi Cui, Masahiro Onozawa, Leigh Samsel, Haven Garber, Hua Zhang, Haiying Qin, Terry J Fry, J. Philip McCoy, Xiaolin Wu, Peter D Aplan, Crystal L Mackall
Journal: Blood (2013)
Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q
Authors: Cecile Bally, Raphael Itzykson, Berangere Gruson, Dreyfus Francois, Virginie Siguret, Anne-Laure Taksin, Benoit de Renzis, Laurence Legros, Xavier Thomas, Krimo Bouabdallah, Pascal Chaibi, Charikleia Kelaidi, Pierre Fenaux, Lionel Ades
Journal: Blood (2011)
Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis
Authors: Ilka Decker, Oluchi C. Ukaegbu, Stacey A. Goodman, Daniel J. Lenihan, Rebecca R Hung, Adetola A. Kassim, Shelton L. Harrell, Kevin McDonagh, Sharon E. Phillips, Kyle T Rawling, Samuel M Rubinstein, Tarsheen K. Sethi, Robert F Cornell
Journal: Blood (2015)
Kringle IV Encoding Domains in the Apo(a) Gene and Serum Lipoprotein(a) Level Do Not Contribute to Avascular Necrosis of Bone (AVN) in Acute Lymphoblastic Leukemia.
Authors: Désirée D.L. Bezemer, Robert D. van Beek, Jules P.P. Meijerink, Sabine M.P.F. de Muinck Keizer-Schrama, Rob Pieters, Marry M. van den Heuvel-Eibrink
Journal: Blood (2004)
Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow
Authors: Hyeongil Kwak, Ombretta Salvucci, Roberto Weigert, Jorge L. Martinez-Torrecuadrada, Mark Henkemeyer, Michael G. Poulos, Jason M. Butler, Giovanna Tosato
Journal: Journal of Clinical Investigation (2016)

Hematopoietic stem and progenitor cells (HSPCs) reside in the bone marrow. Stress signals from cancer and other conditions promote HSPC mobilization into circulation and subsequent homing to tissue microenvironments. HSPC infiltration into tissue microenvironments can influence disease progression; notably, in cancer, HSPCs encourage tumor growth. Here we have uncovered a mutually exclusive distribution of EPHB4 receptors in bone marrow sinusoids and ephrin B2 ligands in hematopoietic cells. We determined that signaling interactions between EPHB4 and ephrin B2 control HSPC mobilization from the bone marrow. In mice, blockade of the EPHB4/ephrin B2 signaling pathway reduced mobilization of HSPCs and other myeloid cells to the circulation. EPHB4/ephrin B2 blockade also reduced HSPC infiltration into tumors as well as tumor progression in murine models of melanoma and mammary cancer. These results identify EPHB4/ephrin B2 signaling as critical to HSPC mobilization from bone marrow and provide a potential strategy for reducing cancer progression by targeting the bone marrow.
Serum Soluble Tumor Necrosis Factor Recepter 2 Levels Is Associated with the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimen
Authors: Nobuhiko Nakamura, Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Takeshi Hara, Senji Kasahara, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2011)
HPV 16 in squamous cell carcinoma of 19th century tonsils
Authors: Nadia Benmoussa, Charlotte Charpentier, Alice-Andrée Mariaggi, Gilles Collin, Diane Descamps, Muriel Hourseau, Beatrix Barry, Sebastien Albert, Annabelle Picard, Patrick Conan, Philippe Charlier
Journal: The Lancet Oncology (2016)
Mental Illness, Release From Prison, and Social Context
Authors: Jeffrey Swanson
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Platelet Tissue Factor Is Localized in Lipid Rafts and Is Associated with GPIb-IX-V Complex in the Membrane: Association between Adhesive and Procoagulant Activities of Platelets.
Authors: Olga Panes, Valeria Matus, Claudia G. Sáez, Alan Gárate, Jaime Pereira, Diego Mezzano
Journal: Blood (2006)
NCO-01NEUROPSYCHOLOGICAL PROFILES IN INDIVIDUALS WITH INCIDENTAL MENINGIOMA
Authors: Alissa M. Butts, Stephen Weigand, Paul D. Brown, Ronald C. Petersen, Clifford R. Jack, Mary M. Machulda, Jane H. Cerhan
Journal: Neuro-Oncology (2015)

Meningioma is a primary brain tumor that is thought to be most often asymptomatic. To our knowledge, no study has attempted to describe neurocognitive function in patients with incidental meningiomas. We hypothesized that relative to controls, individuals with incidental meningioma will have subtle neurocognitive deficits affecting efficiency and attention. To investigate this hypothesis, we utilized the Mayo Clinic Study of Aging (MCSA), which is a population-based sample of Olmsted County, Minnesota residents used to study prevalence, incidence, and risk-factors for Mild Cognitive Impairment and dementia and includes neuropsychological testing and brain MRI every 15 months. Using a text search of radiologist's notes of 2,402 MCSA individuals, mean age 77 ± 8 years and scanned between 2004-2014, we identified 52 subjects (2%) who had at least one meningioma. Most meningiomas were small (94% < 3cm). Each of the 52 subjects was matched to five non-demented MCSA controls (n = 260) on age, sex, and education. Cognitive domains assessed included memory, attention-executive function, language, and visuospatial. Groups did not differ on prevalence of Mild Cognitive Impairment (Meningioma = 13%, Controls = 12%). Across cognitive domains, very similar performance was observed for the two groups (p's ≥ 0.30). Subtle differences in memory performance (0.3 z-scores units; 95% CI - 0.6 to 0.0; p = 0.10) emerged for the evaluation that occurred when the meningioma was at its largest measurement during the study, and may be related to location. Our findings suggest that small meningiomas are clinically benign, but that may change as the tumor evolves, and might be impacted by other factors, such as meningioma location.
CD34+ Subclasses of Blood Stem Cell Grafts Collected After Plerixafor Injection in Non-Hodgkin Lymphoma (NHL) Patients Mobilizing Poorly with Chemotherapy Plus G-CSF
Authors: Esa Jantunen, Ville Varmavuo, Piia Valonen, Taru Kuittinen, Tapio Nousiainen, Pentti Mäntymaa
Journal: Blood (2011)
Treatment for hereditary angioedema with normal C1-INH and specific mutations in the<i>F12</i>gene (HAE-FXII)
Authors: K. Bork, K. Wulff, G. Witzke, J. Hardt
Journal: Allergy (2016)

Hereditary angioedema with normal C1 esterase inhibitor and mutations in the F12 gene (HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. It occurs nearly exclusively in women. We report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug therapies. The study included 72 patients with HAE-FXII. Potential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors. Drug treatment comprised plasma-derived C1 inhibitor (pdC1-INH) for acute swelling attacks and progestins, tranexamic acid, and danazol for the prevention of attacks. Discontinuation of eOC was effective in 25 (89.3%) of 28 women and led to a reduction in the number of attacks (about 90%). After ending hormonal replacement therapy, three of eight women became symptom-free. Three women with exacerbation of HAE-FXII during intake of quinapril or enalapril had no further HAE-FXII attacks after discontinuation of those drugs. Eleven women were treated with pdC1-INH for 143 facial attacks. The duration of the treated facial attacks (mean: 26.6 h; SD: 10.1 h) was significantly shorter than that of the previous 88 untreated facial attacks in the same women (mean: 64.1 h; SD: 28.0 h; P < 0.01). The mean reduction in attack frequency was 99.8% under progestins after discontinuing eOC (16 women), 93.8% under tranexamic acid (four women), and 100% under danazol (three women). For patients with HAE-FXII, various treatment options are available which completely or at least partially reduce the number or duration of attacks.
Two Unusual Sites of Colon Cancer Metastases and a Rare Thyroid Lymphoma
Authors: Elie B. Choufani, Harold L. Lazar, Kevan L. Hartshorn
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.15.3574 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11481366 Two Unusual Sites of Colon Cancer Metastases and a Rare Thyroid Lymphoma Case 2. Chemotherapy-Responsive Right Artial Metastasis From Colon Carcinoma Elie B. ChoufanixElie B. ChoufaniSearch for articles by this author , Harold L. LazarxHarold L. LazarSearch for articles by this author , Kevan L. HartshornxKevan L. HartshornSearch for articles by this author Show More Boston Medical Center and Boston University School of Medicine, Boston, MA https://doi.org/10.1200/JCO.2001.19.15.3574 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
A Single-Centre Series of 40 Patients with Bone-Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia; High Rates of Sustained Response to Oral Methotrexate
Authors: Christopher Fox, Talha Munir, Ian Carter, Sturch Elaine, Faith Richardson, Andrew McMillan, Simon O'Connor, Andrew Haynes
Journal: Blood (2012)
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
Authors: Lili Wang, Angela N. Brooks, Jean Fan, Youzhong Wan, Rutendo Gambe, Shuqiang Li, Sarah Hergert, Shanye Yin, Samuel S. Freeman, Joshua Z. Levin, Lin Fan, Michael Seiler, Silvia Buonamici, Peter G. Smith, Kevin F. Chau, Carrie L. Cibulskis, Wandi Zhang, Laura Z. Rassenti, Emanuela M. Ghia, Thomas J. Kipps, Stacey Fernandes, Donald B. Bloch, Dylan Kotliar, Dan A. Landau, Sachet A. Shukla, Jon C. Aster, Robin Reed, David S. DeLuca, Jennifer R. Brown, Donna Neuberg, Gad Getz, Kenneth J. Livak, Matthew M. Meyerson, Peter V. Kharchenko, Catherine J. Wu
Journal: Cancer Cell (2016)
Adenotonsillectomy for childhood obstructive sleep apnoea reduces thoraco-abdominal asynchrony but spontaneous apnoea−hypopnoea index normalisation does not
Authors: Xiao Liu, Sarah Immanuel, Yvonne Pamula, Declan Kennedy, James Martin, Mathias Baumert
Journal: European Respiratory Journal (2016)

The efficacy of adenotonsillectomy for treating obstructive sleep apnoea syndrome (OSAS) in children has been established, but its precise effects on inspiratory effort are not well documented. In 353 children enrolled in the Childhood Adenotonsillectomy Trial, randomised to undergo either early adenotonsillectomy (n=182) or a strategy of watchful waiting with supportive care (WWSC) (n=171), thoraco-abdominal asynchrony (TAA) was analysed during quiet, non-apnoeic and non-hypopnoeic breathing during sleep at baseline and at 7 months using overnight polysomnography. Children who underwent early adenotonsillectomy demonstrated a reduction in TAA post-surgery while the WWSC arm showed no change. On assessing TAA with regard to normalisation of clinical polysomnography findings at follow-up, TAA was reduced in children who had surgical resolution of OSAS (based on apnoea–hypopnoea index), but not in children who displayed spontaneous normalisation of apnoea–hypopnoea index. In the latter group, TAA was inversely correlated with quality of life. We conclude that adenotonsillectomy reduces TAA during quiet sleep. Monitoring of instantaneous TAA may yield additional insight in the dynamic changes of inspiratory effort. In combination with traditional indices of obstruction, TAA may more accurately characterise the degree of sleep-disordered breathing in children.